Detalhe da pesquisa
1.
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.
Nature
; 588(7836): 157-163, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33239784
2.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Cancer
; 130(8): 1270-1280, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38153814
3.
Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes.
Ann Hematol
; 2024 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38771499
4.
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
Ann Hematol
; 103(2): 437-442, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38060001
5.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Ann Hematol
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438627
6.
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.
Am J Hematol
; 2024 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38877813
7.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Cancer
; 129(11): 1704-1713, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36932983
8.
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia.
Blood
; 138(7): 571-583, 2021 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33889952
9.
Management of polycythemia vera: A survey of treatment patterns in Italy.
Eur J Haematol
; 110(2): 161-167, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36319575
10.
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Cancer
; 128(13): 2449-2454, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363892
11.
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Br J Haematol
; 197(2): 190-200, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35137397
12.
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.
Blood
; 136(2): 171-182, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32266380
13.
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
Blood
; 135(5): 381-386, 2020 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31869407
14.
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
Ann Hematol
; 101(5): 963-978, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35201417
15.
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Future Oncol
; 18(27): 2987-2997, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950489
16.
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Cancer
; 127(15): 2657-2665, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794557
17.
Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study.
Br J Haematol
; 193(2): 386-396, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33618438
18.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Br J Haematol
; 193(2): 356-368, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33222197
19.
Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series.
Hematol Oncol
; 39(1): 123-128, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32979286
20.
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
Hematol Oncol
; 39(3): 409-418, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33590502